Pharmafile Logo

Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026

June 18, 2026 | ASCO, Congress, Pharma, healthcare, oncology, webinar 

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

- PMLiVE

Join our team for an expert debrief from ASCO® 2026. With a front-row seat across multiple client engagements, we’ll share the scientific highlights, attendee perspectives and strategic lessons from one of oncology’s most important annual gatherings, while exploring what smarter, more measurable congress engagement looks like in practice.

What we’ll cover

  • Key scientific and strategic themes emerging from ASCO® 2026
  • Attendee perspectives and trends shaping oncology congress engagement
  • Lessons from real-world client engagements and launch environments
  • Smarter approaches to congress strategy, engagement and measurement
  • Opportunities to drive sharper strategic decision-making through congress insights

The experts shaping the conversation

  • Mark Jackson, Managing Director, Emota, an Inizio Engage company
  • Matt Hoelzle, Chief Medical Officer, Inizio Evoke
  • Simon Davenport, Global Head of Exhibitions and Environments, Emota, an Inizio Engage company
  • Nick Bellomo, Director of Technology and Engagement, Inizio Medical
  • Jo Ann Saitta, Global Head of Data Strategy, Analytics, and AI, Inizio Ignite
  • Lynsey Holbrook, Global Client Development Director, Emota, an Inizio Engage company
Watch the webcast here.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Demand assessment research video

Head of Business Analytics Tom Nolte and Associate Director Will Tolley discuss demand assessment research – the various techniques and when in a product’s stage of development a demand assessment…

Men vs Women in emerging markets

Our latest interactive infographic compares male vs female health characteristics in the BRIC emerging marketS

South Korea: The next global player?

In this paper, we will explore some of the key trends and outlooks for South Korea in more detail, including what lies behind its presence at the extremes of two…

20 questions: Round 4

As it’s our 20th year anniversary, we invited our employees to play our version of 20 questions – this month “What’s been the funniest thing to happen to you whilst you’ve…

Will gene therapies finally be commercially viable to pharma?

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when…

Wargaming in HCV

The challenge:Our client had a product ready for launch in the HCV landscape. A number of new competitor products were expected to alter the market dynamics. Given the stage of…

Living with Lupus: Breaking the Silence

Published in eyeforpharma July 2017 by Mariel Metcalfe

Demystifying human-centred design: the application of iterative, human-centric approaches in global health market research

One of the biggest buzz topics in the global health community over the last couple of years has been human-centred design, also referred to as behaviour-centred design. In this blog…

In the news: What will the UK’s recent general election result and ongoing Brexit negotiations mean for DfID funding for global health?

The UK’s Department for International Development (DfID) was established in 1997 with a mandate to tackle world poverty. Since its inception, it has played a major role in the global…

TRIO OF HIRES SIGNAL PEGASUS’ NORTHERN GRIT

Growth trend continues at ‘health first, sector second’ agencyPegasus, an Ashfield company, part of UDG Healthcare plc, has announced further growth of its Pharma and Life Sciences division with the…